Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewS 18986
Description: Positive allosteric modulator of AMPA receptors
Chemical Name: (3aS)-2,3,3a,4-Tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine-5,5-dioxide
Purity: ≥98% (HPLC)
Biological Activity for S 18986
S 18986 is a positive allosteric modulator of AMPA receptors. Exhibits cognitive enhancing properties in rodent behavioral models. Brain penetrant.
Technical Data for S 18986
| M. Wt | 224.28 |
| Formula | C10H12N2O2S |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 175340-20-2 |
| PubChem ID | 637863 |
| InChI Key | MNTIJYGEITVWHU-SNVBAGLBSA-N |
| Smiles | O=S2(C1=CC=CC=C1N(CCC3)[C@@]3([H])N2)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for S 18986
References for S 18986
References are publications that support the biological activity of the product.
Desos et al (1996) Enantioselective synthesis of a pyrrolo-benzothiadiazine derivative S 18986, a new AMPA receptor positive modulator. Bioorg.Med.Chem.Lett. 6 3003
Lockhart et al (2000) (S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices. Eur.J.Pharmacol. 401 145 PMID: 10924919
Bourasset et al (2005) Neuropharmacokinetics of a new α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat. Drug Metab.Dispos. 33 1137 PMID: 15860654
View Related Products by Target
View Related Products by Product Action
Keywords: S 18986, S 18986 supplier, S18986, pam, positive, allosteric, modulators, potentiators, ampa, cognitive, enhancers, enhancement, brain, penetrant, bbb, AMPA, Receptors, 3911, Tocris Bioscience
Citations for S 18986
Citations are publications that use Tocris products.
Currently there are no citations for S 18986.
Reviews for S 18986
There are currently no reviews for this product. Be the first to review S 18986 and earn rewards!
Have you used S 18986?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.